Fig. 2

SAA as a prognostic biomarker in ovarian cancer. a. Heat-map of SAA between pretreatment (A) and post-treatment(B). n = 20, ** P < 0.01. b. Comparison of SAA expression in serum among healthy control group, ovary benign and cancer group, P = 0.189,0.000,0.000 c. High-FIGO stage patients (III + IV), SAA expression in serum was significant difference with healthy group, p = 0.0001. Low-FIGO stage patients(I + II), SAA expression in serum was difference with healthy group, p = 0. 0162. Between high-FIGO stage patients (III + IV) and low-FIGO stage patients(I + II), SAA expression in serum was difference, p = 0.0232. d. ROC curve of sensitivity versus specificity of SAA, CA125, HE4, and combinations of three makers. In combined detection of SAA, CA125, and HE4, AUC = 0.945, Sensitivity = 0.892, Specificity =0.973. Kruskal–Wallis /one-way ANOVA tests were used to test the statistical significant (B,C). (* P < 0.05, *** P < 0.001, **** P < 0.0001)